Marker Therapeutics Inc. has announced a collaboration with Cellipont Bioservices to advance the cGMP manufacturing of their lead Multi-Antigen Recognizing $(MAR)$-T cell therapy, MT-601, for patients with lymphoma. This partnership aims to support the scale-up and production of MT-601 for the ongoing Phase 1 APOLLO study, which is investigating the therapy in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or for whom such therapy is not an option. The APOLLO study has already reported favorable safety results and objective responses in 78% of participants, with a 44.4% complete response rate observed in some patients as early as four weeks post-infusion. The collaboration is designed to accelerate clinical supply and prepare for potential pivotal trials and commercial readiness.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.